Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Praluent Reviewers

Executive Summary

FDA staff involved in review of Sanofi and Regeneron's PCSK9 inhibitor alirocumab for reducing LDL-cholesterol.

You may also be interested in...



Praluent Sponsors Set Tone For PCSK9 Labeling, Post-Marketing Negotiations

Sanofi and Regeneron's 'extended negotiations' with FDA on requirements would later apply to Amgen's Repatha.

Liver Injury Case Sparked Flurry Of Concern Late In Praluent Review

MedWatch report of hepatotoxicity prompted two 'urgent information requests' to sponsors a month before alirocumab user fee goal date.

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel